CStone of Suzhou Enters $386 Million, Three-Drug Deal with Boston's Blueprint

CStone Pharma of Suzhou signed a $386 million agreement for rights to three drug candidates discovered by Blueprint Medicines of Cambridge, Mass. CStone will have exclusive Greater China rights to the three Blueprint clinical-stage oral oncology medicines, each targeting genomically defined conditions. CStone paid $40 million upfront for the candidates, and it will make payments totaling up to $118.5 million for clinical milestones and $227.5 million for sales levels, plus royalties. Last month, the company raised $260 million in a B round to support its 13 immunocology candidates. More details.... Stock Symbol: (NSDQ: BPMC) Share this with colleagues: // //